CDTX Cidara Therapeutics Inc

Cidara Therapeutics Inc mainly develops anti-infective drugs in the United States. It attends to serious fungal infections through its drug candidates and proprietary immunotherapy technology platform, CloudbreakTM.

$0.52
As of 06/24/2022     IEX book   CBOE book

---

Security Information

---

Category1:  US Equity
Category2:  Common stocks
Category3:  Micro cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  USA
IPO date:  04/15/2015
Outstanding shares:  69,049,497
Average volume:  351,308
Market cap:   $38,315,566
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
Sedol:      

---

Valuation   (See tab for details)

---

PE ratio:   -0.81
PB ratio:   7.22
PS ratio:   0.71
Return on equity:   -856.49%
Net income %:   -78.23%